Resources

Cell-derived Nanoparticles: A New Paradigm for CAR-T Cell Activation and Manufacturing; Presentations by UCSF & Ori Biotech

Synecta enhances lentiviral transduction and manufacturing efficiency in closed, automated cell therapy platform

Generation of scalable off-the-shelf iNKT therapies with Synecta T1

Synecta T1 and Flowfect® Enhance Non-Viral Engineering Efficiency and Manufacturing Scalability of CD19-Directed CAR-T Cells For Hematologic Malignancies

Synecta T1 Enables Accelerated, Potent T Cell Expansion For Scalable Adoptive Immunotherapy Manufacturing

Cytiva’s Fast Trak™ (services for process development and training) evaluated Synecta T1 across both small- and large-scale expansion systems to benchmark performance against a conventional activation reagent to assess fold expansion, viability, and scalability in T-cell manufacturing workflows.